Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Phase 2
Not yet recruiting
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 36
- Registration Number
- NCT06116578
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer
Phase 1
Recruiting
- Conditions
- Head and Neck CarcinomaAdult Disease
- Interventions
- Biological: HPVDC injection level dose 1Biological: HPVDC injection level dose 2Biological: placebo injection level dose 1Biological: placebo injection level dose 2
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 24
- Registration Number
- NCT06007092
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Optimization of an Online Stepwise Therapeutic Device Based on a Cognitive-behavioral Approach for Cancer Patients With Insomnia
Not Applicable
Active, not recruiting
- Conditions
- InsomniaCancer
- Interventions
- Other: Self screeningOther: Phone callOther: Online questionnaires
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 322
- Registration Number
- NCT05977062
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
🇫🇷Gustave Roussy, Villejuif, France
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Phase 1
Recruiting
- Conditions
- Locally-advanced Rectal Cancer
- Interventions
- Drug: mFOLFIRINOXRadiation: Pelvic radiotherapy LCRTRadiation: Pelvic radiotherapy SCRTDrug: FOLFOX4Drug: CAPOX
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 78
- Registration Number
- NCT05912075
- Locations
- 🇫🇷
Centre Léon Bérard, Lyon, Rhöne, France
🇫🇷Gustave Roussy, Villejuif, Val De Marne, France
Engineering Immune Organoids to Study Pediatric Cancer
Not Applicable
Recruiting
- Conditions
- Brain TumorKidney TumorSarcomaNeuroblastoma
- Interventions
- Procedure: Skin biopsyProcedure: Fresh tumor sampleBiological: Blood sampleProcedure: Healthy tissue from the tumorProcedure: Spinal cerebrospinal fluid (SCF)
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 44
- Registration Number
- NCT05890781
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant
Not Applicable
Recruiting
- Conditions
- Germ Cell Tumor
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 180
- Registration Number
- NCT05889585
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors
Phase 3
Recruiting
- Conditions
- Germ Cell Tumor
- Interventions
- Drug: Thromboprophylaxis
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 387
- Registration Number
- NCT05874063
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷CHU de Brest, Brest, France
🇫🇷Groupe Hospitalier Mutualiste de Grenoble, Grenoble, France
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 24
- Registration Number
- NCT05830084
- Locations
- 🇦🇺
Perth Children's Hospital, Perth, Australia
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇮🇹Istituto Nazionale dei Tumori, Milan, Italy
Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors
Not Applicable
Recruiting
- Conditions
- Non-Seminomatous Germ Cell Tumor
- Interventions
- Drug: Dose-dense regimenProcedure: Early tumor resection or HD-CTDrug: BEP Protocol
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 150
- Registration Number
- NCT05705687
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma
Not Applicable
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Device: QuiremSpheres
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 33
- Registration Number
- NCT05705791
- Locations
- 🇫🇷
AP-HP Hôpital Beaujon, Clichy, France
🇫🇷Centre Georges-François Leclerc, Dijon, France
🇫🇷CHU François Mitterand, Dijon, France